Found: 69
Select item for more details and to access through your institution.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 7, p. 2299, doi. 10.1007/s00277-024-05665-4
- By:
- Publication type:
- Article
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 12, p. 917, doi. 10.1016/j.clml.2023.08.018
- By:
- Publication type:
- Article
Mass/heat transfer analogy method in the research of convective fluid flow through channels with a specific geometry.
- Published in:
- Archives of Thermodynamics, 2023, v. 44, n. 4, p. 427, doi. 10.24425/ather.2023.149722
- By:
- Publication type:
- Article
Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study.
- Published in:
- Acta Haematologica, 2023, v. 146, n. 5, p. 373, doi. 10.1159/000531146
- By:
- Publication type:
- Article
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 9, p. e286, doi. 10.1016/j.clml.2023.06.001
- By:
- Publication type:
- Article
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 7, p. 491, doi. 10.1016/j.clml.2023.03.007
- By:
- Publication type:
- Article
SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA.
- Published in:
- Acta Haematologica Polonica, 2023, v. 54, n. 2, p. 82, doi. 10.5603/AHP.a2023.0016
- By:
- Publication type:
- Article
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
- Published in:
- Trials, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s13063-022-06982-7
- By:
- Publication type:
- Article
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies.
- Published in:
- Trials, 2023, v. 24, n. 1, p. 1, doi. 10.1186/s13063-022-06982-7
- By:
- Publication type:
- Article
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Acute Myeloid Leukemia: A Single-Centre Experience.
- Published in:
- 2023
- By:
- Publication type:
- journal article
MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 377
- By:
- Publication type:
- Article
Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM).
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 388
- By:
- Publication type:
- Article
SEQUOIA: results of a phase 3 randomized study of Zanubrutinib versus Bendamustine + Rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 32
- By:
- Publication type:
- Article
Allogeneic hematopoietic stem cells transplantation for relapsed and refractory acute myeloid leukemia in a single center experience.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 73
- By:
- Publication type:
- Article
Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing.
- Published in:
- Biomedicines, 2022, v. 10, n. 7, p. N.PAG, doi. 10.3390/biomedicines10071674
- By:
- Publication type:
- Article
Mass/Heat Transfer Analogy Method in the Research on Convective Fluid Flow through a System of Long Square Mini-Channels.
- Published in:
- Materials (1996-1944), 2022, v. 15, n. 13, p. 4617, doi. 10.3390/ma15134617
- By:
- Publication type:
- Article
Diagnosis and treatment of immune thrombocytopenia in Poland.
- Published in:
- Hematology in Clinical Practice, 2022, v. 13, n. 2, p. 49, doi. 10.5603/HCP.a2022.0013
- By:
- Publication type:
- Article
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 11, p. 785, doi. 10.1016/j.clml.2021.06.005
- By:
- Publication type:
- Article
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S143, doi. 10.1016/S2152-2650(21)02320-X
- By:
- Publication type:
- Article
P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02337-5
- By:
- Publication type:
- Article
Poster: CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01393-8
- By:
- Publication type:
- Article
Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01453-1
- By:
- Publication type:
- Article
Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01537-8
- By:
- Publication type:
- Article
CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S316, doi. 10.1016/S2152-2650(21)01747-X
- By:
- Publication type:
- Article
MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S353, doi. 10.1016/S2152-2650(21)01817-6
- By:
- Publication type:
- Article
IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S404, doi. 10.1016/S2152-2650(21)01912-1
- By:
- Publication type:
- Article
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 4, p. 784, doi. 10.1111/bjh.17541
- By:
- Publication type:
- Article
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 132, doi. 10.1111/bjh.17435
- By:
- Publication type:
- Article
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Polish Experts' Position Statement on the use of granulocyte colony-stimulating factor in the treatment of chronic lymphocytic leukemia with venetoclax combined with rituximab.
- Published in:
- Hematology in Clinical Practice, 2021, v. 33, n. 2, p. 67, doi. 10.5603/HCP.2021.0008
- By:
- Publication type:
- Article
Mean Platelet Volume Has Prognostic Value in Chronic Lymphocytic Leukemia.
- Published in:
- Cancer Management & Research, 2020, v. 12, p. 9977, doi. 10.2147/CMAR.S246385
- By:
- Publication type:
- Article
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
- By:
- Publication type:
- Article
A five‐year follow‐up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 5, p. 736, doi. 10.1111/bjh.16625
- By:
- Publication type:
- Article
The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of patients with multiple myeloma.
- Published in:
- Polish Archives of Internal Medicine, 2020, v. 130, n. 6, p. 483, doi. 10.20452/pamw.15316
- By:
- Publication type:
- Article
Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 4, p. 689, doi. 10.1111/bjh.16429
- By:
- Publication type:
- Article
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 12, p. 1, doi. 10.1038/s41408-019-0260-2
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e15, doi. 10.1016/j.clml.2019.09.022
- By:
- Publication type:
- Article
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e164, doi. 10.1016/j.clml.2019.09.275
- By:
- Publication type:
- Article
Skuteczność zastosowania ruksolitynibu u chorej z wtórnym włóknieniem szpiku w przebiegu wieloletniej czerwienicy prawdziwej powikłanej zakrzepicą w układzie wrotnym.
- Published in:
- Hematology (2081-0768), 2019, v. 10, p. A23, doi. 10.5603/Hem.2019.0007
- By:
- Publication type:
- Article
Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S274, doi. 10.1016/j.clml.2019.07.205
- By:
- Publication type:
- Article
Zachowania żywieniowe chorych na nowotwory hematologiczne -- prospektywne badanie jednoośrodkowe.
- Published in:
- Hematology (2081-0768), 2019, v. 10, n. 3, p. 124, doi. 10.5603/Hem.2019.0026
- By:
- Publication type:
- Article
Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma.
- Published in:
- British Journal of Haematology, 2019, v. 184, n. 4, p. 536, doi. 10.1111/bjh.15679
- By:
- Publication type:
- Article
Single‐agent ibrutinib versus chemoimmunotherapy regimens for treatment‐naïve patients with chronic lymphocytic leukemia: A cross‐trial comparison of phase 3 studies.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 11, p. 1402, doi. 10.1002/ajh.25259
- By:
- Publication type:
- Article
Recommendations for the diagnosis and treatment of patients with polycythaemia vera.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 5, p. 654, doi. 10.1111/ejh.13156
- By:
- Publication type:
- Article
Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S253, doi. 10.1016/j.clml.2018.07.155
- By:
- Publication type:
- Article
IMPROVING THE EFFECTIVENESS OF OBESITY TREATMENT BY COMBINING A DIET AND MOTIVATIONAL TECHNIQUES.
- Published in:
- Annals of the National Institute of Hygiene / Roczniki Państwowego Zakładu Higieny, 2018, v. 69, n. 3, p. 299
- By:
- Publication type:
- Article
Ostra białaczka z koekspresją antygenów limfoi mieloidalnych oraz masywną limfadenopatią jako problem diagnostyczny i terapeutyczny.
- Published in:
- Hematology (2081-0768), 2018, v. 9, n. 2, p. 146, doi. 10.5603/Hem.2018.0018
- By:
- Publication type:
- Article
The importance of antiangiogenic effect in multiple myeloma treatment.
- Published in:
- Advances in Clinical & Experimental Medicine, 2018, v. 27, n. 2, p. 291, doi. 10.17219/acem/68826
- By:
- Publication type:
- Article
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.
- Published in:
- Annals of Hematology, 2017, v. 96, n. 10, p. 1693, doi. 10.1007/s00277-017-3084-9
- By:
- Publication type:
- Article
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 896, doi. 10.1111/bjh.14787
- By:
- Publication type:
- Article